LIVE
BLUE
bluebird bio, Inc. · Healthcare
N/A
N/A this month
VERSUS
⟷
COMPARE
CRSP
CRISPR Therapeutics AG · Healthcare
$50.81
+2.03% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
BLUE
0
CRSP
0
Comparison scoreboard
MIXED SETUPAI Score
BLUE N/A
CRSP 38.3
1Y Return
BLUE N/A
CRSP -9.94%
Fwd P/E
BLUE N/A
CRSP -13.13
Target Up.
BLUE N/A
CRSP +66.70%
Op. Margin
BLUE N/A
CRSP N/A
Metrics last refreshed: 7/14/2026
Quick take
BLUE vs CRSP: bluebird bio vs CRISPR Therapeutics Stock Comparison: AI Score, Valuation, Performance and Upside
bluebird bio and CRISPR Therapeutics both compete in sickle cell disease with approved one-time gene treatments (Lyfgenia vs Casgevy), but CRISPR Therapeutics has a stronger commercial partner (Vertex) and a more robust balance sheet. bluebird has more approved indications but significantly weaker commercial execution and more fragile finances.
BLUE vs CRSP is a financially fragile gene therapy pioneer versus the CRISPR gene editing leader with Vertex commercial partnership — both compete in sickle cell disease, but CRISPR Therapeutics has superior financial strength, commercial backing, and technology breadth.
Live analysis · updated 7/14/2026
BLUE and CRSP are closely matched — they split the tracked metrics evenly.
Normalized 1Y performance
BLUE
CRSP
Not enough data to chart yet.
Recent returns
BLUE
CRSP
Analyst price targets & sentiment
BLUE
Price target data unavailable
N/A
CRSP · 20 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$44.00
analyst high$291.00
analyst mean$84.70
current price$50.81
+66.7% upside to analyst mean
Who should consider this stock?
BLUE may suit investors who:
- →believe bluebird's three approved gene therapies will eventually find commercial traction
- →want speculative exposure to a gene therapy pioneer at a deeply distressed valuation
- →are comfortable with high execution risk, cash runway uncertainty, and commercial ramp challenges
- →believe lentiviral vector gene therapy has advantages for specific indications vs CRISPR approaches
CRSP may suit investors who:
- →prefer the CRISPR gene editing leader with Vertex commercial partnership for Casgevy
- →want gene editing exposure with a more robust balance sheet and clinical pipeline
- →value CRISPR's technology platform breadth across sickle cell, diabetes, and oncology
- →prefer a lower-risk genetic medicine bet than bluebird's financially stressed situation
Performance & AI score
| Metric | BLUE | CRSP |
|---|---|---|
| AI score | N/A | 38.3 |
| AI rank | N/A | #1357 |
| Latest close | N/A | $50.81 |
| 1M return | N/A | +2.03% |
| 6M return | N/A | -8.12% |
| 1Y return | N/A | -9.94% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | BLUE | CRSP |
|---|---|---|
| 1Y ago | N/A | $9.01K (-9.9%) started 2025-07-14 |
| 5Y ago | N/A | $3.9K (-61.0%) started 2021-07-14 |
| 10Y ago | N/A | $36.06K (+260.6%) started 2016-10-19 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | BLUE | CRSP |
|---|---|---|
| Market cap | N/A | $5B |
| Trailing P/E | N/A | N/A |
| Forward P/E | N/A | -13.13 |
| Price/Sales | 0.58 | 1219.59 |
| EV/Revenue | N/A | 787.00 |
| Analyst target | N/A | $84.70 |
| Target upside | N/A | +66.70% |
Growth, profitability & risk
| Metric | BLUE | CRSP |
|---|---|---|
| Revenue growth | N/A | 68.60% |
| Earnings growth | N/A | N/A |
| EPS growth | N/A | N/A |
| FCF margin | N/A | -6358.66% |
| Operating margin | N/A | N/A |
| Profit margin | N/A | 0.00% |
| ROIC proxy | N/A | -31.21% |
| Return on equity | N/A | -31.21% |
| Dividend yield | N/A | 0.00% |
| Beta | 0.49 | 1.70 |
| Debt/equity | N/A | 43.41 |
| Current ratio | N/A | 17.96 |
| Quick ratio | N/A | 17.92 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
BLUE max drawdownN/A
CRSP max drawdown42.25%
BLUE max wkly dropN/A
CRSP max wkly drop18.19%
5Y risk snapshot
BLUE max drawdownN/A
CRSP max drawdown77.31%
BLUE max wkly dropN/A
CRSP max wkly drop21.49%
10Y risk snapshot
BLUE max drawdownN/A
CRSP max drawdown85.11%
BLUE max wkly dropN/A
CRSP max wkly drop30.47%
Performance metrics by period
| Period | Metric | BLUE | CRSP |
|---|---|---|---|
| 1Y | Growth | N/A | -9.94% |
| CAGR | N/A | -9.95% | |
| Sharpe ratio | N/A | 0.07 | |
| Max drawdown | N/A | 42.25% | |
| Max daily drop | N/A | 11.59% | |
| Max wkly drop | N/A | 18.19% | |
| 5Y | Growth | N/A | -61.01% |
| CAGR | N/A | -17.17% | |
| Sharpe ratio | N/A | -0.09 | |
| Max drawdown | N/A | 77.31% | |
| Max daily drop | N/A | 13.32% | |
| Max wkly drop | N/A | 21.49% | |
| 10Y | Growth | N/A | +260.61% |
| CAGR | N/A | +14.09% | |
| Sharpe ratio | N/A | 0.45 | |
| Max drawdown | N/A | 85.11% | |
| Max daily drop | N/A | 17.10% | |
| Max wkly drop | N/A | 30.47% |
Business comparison
| Category | BLUE | CRSP |
|---|---|---|
| Company | bluebird bio, Inc. | CRISPR Therapeutics AG |
| Sector | Healthcare | Healthcare |
| Industry | N/A | N/A |
| Core business | Gene therapy company with three approved gene therapies: Zynteglo (beta-thalassemia), Lyfgenia (sickle cell disease), and Skysona (cerebral adrenoleukodystrophy). bluebird uses lentiviral vector delivery to correct disease-causing genetic mutations. | Gene editing company with Casgevy (the world's first approved CRISPR therapy for sickle cell and beta-thalassemia co-developed with Vertex) and a pipeline in diabetes and oncology. |
| Investor focus | Commercial ramp of Zynteglo and Lyfgenia, patient identification and treatment site expansion, reimbursement outcomes, and cash runway toward commercial sustainability. | Casgevy commercial adoption, pipeline advancement in diabetes (CTX112) and CAR-T oncology, and next-generation in vivo CRISPR delivery. |
BLUE strengths
- →bluebird has three approved gene therapies — more regulatory approvals than most gene therapy companies
- →Lyfgenia directly competes with Casgevy (CRISPR) for sickle cell patients — a validated market with proven payer acceptance
- →Lentiviral vector delivery is a well-understood and clinically proven gene delivery approach
CRSP strengths
- →Casgevy is co-commercialized with Vertex's large commercial infrastructure, giving CRSP a competitive advantage in sickle cell market access
- →CRISPR-Cas9 is a more flexible gene editing platform than lentiviral vectors for future disease applications
- →Strong balance sheet from Vertex milestone payments provides multi-year runway
Risks to watch — BLUE
- →Commercial uptake has been extremely slow due to the high cost ($3M+) and complex patient identification process
- →bluebird has faced repeated cash crises and has depended on equity issuance to fund operations
- →Casgevy (CRISPR/Vertex) competes directly with Lyfgenia in sickle cell disease — a better-funded competitor
Risks to watch — CRSP
- →Casgevy competes with bluebird's Lyfgenia — both treat sickle cell disease with similar one-time gene treatment approaches
- →Casgevy's complex administration (bone marrow conditioning) limits treatment site capacity
- →CRISPR's in vivo delivery for future programs remains technically unproven at commercial scale
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →